An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Trial Profile

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Medicenna Therapeutics
  • Most Recent Events

    • 16 Nov 2017 According to a Medicenna Therapeutics media release, additional clinical data from the first 15 patients treated to date in this trial were presented at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO).
    • 14 Nov 2017 According to a Medicenna Therapeutics media release, results were presented Cancer Prevention and Research Conference held from November 13-14, 2017 in Austin.
    • 14 Nov 2017 Results published in the Medicenna Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top